Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07224425 · ClinicalTrials.gov registry record · Phase 1

A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps

A Phase 1 study of Melanoma and Solid Tumours, sponsored by Boehringer Ingelheim.

Recruiting
Registry status
Phase 1
Development phase
69
Enrollment target
5
Study locations

NCT07224425 is a Phase 1 study of Melanoma and Solid Tumours that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 69 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07224425, a Phase 1 study of Melanoma and Solid Tumours, is actively recruiting participants, sponsored by Boehringer Ingelheim.

RECRUITING
Registry status
Phase 1
Development phase
69 participants
Enrollment target
5
Study locations

Study Summary

This study is open to adults with advanced cancer (solid tumours) for whom previous treatment was not successful, or no treatment exists. The study tests different doses of BI 3810944 to find out which doses they can tolerate. Another purpose is to identify the most suitable dose of BI 3810944 and to find out whether it helps people with advanced cancer. BI 3810944 may help fight cancer. Participants get BI 3810944 usually once every 3 weeks. At treatment start, it is given once a week for a short time. Participants may continue to get BI 3810944 as long as they benefit from treatment but no longer than 2 years. During this time, they regularly visit the study site. The first study visits include overnight stays at the hospital. At the visits, study doctors check participants' health, take necessary laboratory tests, and note any unwanted effects. The doctors also regularly check the size of the tumour with imaging methods.

Conditions Studied

Melanoma Solid Tumours

Interventions

  • DRUG BI 3810944

Study Locations (5)

Other

  • Cliniques Universitaires Saint-Luc - Brussels
  • UZ Leuven - Leuven
  • Radboud Universitair Medisch Centrum - Nijmegen

Kentucky

  • University of Louisville - Louisville

Tennessee

  • Tennessee Oncology, PLLC - Elliston Place Plaza DDU - Nashville

Trial Details

FieldValue
Enrollment Target 69 participants
Start Date 2026-02-24
Est. Completion 2029-10-05
Phase Phase 1

Sponsor

Boehringer Ingelheim

515 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07224425

The ClinicalTrials.gov registry entry for NCT07224425 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (90% lower). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which BI 3810944 is the first listed.

NCT07224425 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Other, Kentucky, Tennessee.

Frequently Asked Questions

What is clinical trial NCT07224425 about?

NCT07224425 is a clinical study titled "A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps". This study is open to adults with advanced cancer (solid tumours) for whom previous treatment was not successful, or no treatment exists. The study tests different doses of BI 3810944 to find out which doses they can tolerate. Another purpose is to identify the most suitable dose of BI 3810944 and t...

What is the current status of trial NCT07224425?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 69 participants. The study started on 2026-02-24. Estimated completion is 2029-10-05.

What conditions does trial NCT07224425 study?

This clinical trial studies the following conditions: Melanoma, Solid Tumours.

What interventions are being tested in trial NCT07224425?

The interventions under investigation include: BI 3810944 (DRUG).

Who is sponsoring clinical trial NCT07224425?

This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07224425 being conducted?

This trial has 5 study locations across Kentucky, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Melanoma

All registered trials for this condition

Solid Tumours

All registered trials for this condition

Kentucky

All trials with a study site in Kentucky

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.